FASN inhibitors, such as TVB3664, prevent HCC development driven by PTEN/c-MET or AKT/NRAS mutations and enhance the efficacy of sorafenib or cabozantinib in c-Myc-driven HCC (113). Here, AKT1 is linked to hepatocellular carcinoma.